Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Rituximab efficacy in cancer therapy depends in part on induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of the membrane attack complex, thereby inhibiting induction of CDC. hCD59 is highly expressed in B-cell non-Hodgkin's lymphoma (NHL), and upregulation of hCD59 is an important determinant of the sensitivity of NHL cells to rituximab treatment. Here, we report that the potent hCD59 inhibitor rILYd4 enhances CDC in vitro and in vivo, thereby sensitizing rituximab-resistant lymphoma cells and primary chronic lymphocytic leukemia cells (CLL) to rituximab treatment. By defining pharmcokinetic/pharmacodynamic profiles of rILYd4 in mice, we showed that by itself rILYd4 does not adversely mediate in vivo hemolysis of hCD59-expressing erythrocytes. Increasing expression levels of the complement regulators CD59 and CD55 in rituximab-resistant cells occur due to selection of preexisting clones rather than de novo induction of these proteins. Moreover, lymphoma cells overexpressing CD59 were directly responsible for the resistance to rituximab-mediated CDC therapy. Our results rationalize the use of rILYd4 as a therapeutic adjuvant for rituximab treatment of rituximab-resistant lymphoma and CLL. Furthermore, they suggest that preemptive elimination of CD59-overexpressing subpopulations along with rituximab treatment may be a useful approach to ablate or conquer rituximab resistance.
Department of Medicine, Brigham and Women's Hospital, and Laboratory for Translational Research, Harvard Medical School, Cambridge, Massachusetts 02139, USA. weiguo_hu@hms.harvard.edu
Weiguo
W
Hu
Xiaowen
X
Ge
Tao
T
You
Ting
T
Xu
Jinyan
J
Zhang
Gongxiong
G
Wu
Zhihai
Z
Peng
Michael
M
Chorev
Bertal H
BH
Aktas
Jose A
JA
Halperin
Jennifer R
JR
Brown
Xuebin
X
Qin
D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology; D001430:Bacteriocins / Q000235:genetics / Q000494:pharmacology*; D018957:CD59 Antigens / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D045744:Cell Line, Tumor; D003165:Complement System Proteins / Q000276:immunology / Q000378:metabolism*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects* / Q000276:immunology; D003603:Cytotoxins / Q000235:genetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D008819:Mice, Nude; D011994:Recombinant Proteins / Q000494:pharmacology; D000069283:Rituximab; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001430:Bacteriocins; D018957:CD59 Antigens; D003603:Cytotoxins; D011994:Recombinant Proteins; C403910:intermedilysin protein, Streptococcus intermedius; D000069283:Rituximab; D003165:Complement System Proteins
Nat Med. 2000 Apr;6(4):443-6
10742152
Blood. 2000 Jun 15;95(12):3900-8
10845926
J Clin Oncol. 2003 Apr 15;21(8):1466-71
12697868
J Exp Med. 1986 May 1;163(5):1150-61
2422313
Clin Cancer Res. 2006 Jul 1;12(13):4027-35
16818702
Blood. 2001 Nov 1;98(9):2771-7
11675350
Anticancer Res. 2004 Sep-Oct;24(5C):3343-53
15515430
Anticancer Res. 2004 Sep-Oct;24(5C):3367-72
15515433
J Immunol. 2008 Jul 1;181(1):822-32
18566448
Cancer Immunol Immunother. 2007 Jul;56(7):1107-17
17160682
J Biochem. 1989 Oct;106(4):555-7
2606909
Clin Cancer Res. 2009 Feb 1;15(3):851-7
19188155
Blood. 1999 Oct 1;94(7):2217-24
10498591
Nat Struct Mol Biol. 2004 Dec;11(12):1173-8
15543155
Blood. 2008 Feb 1;111(3):1456-63
18024795
N Engl J Med. 1985 Apr 25;312(17):1091-7
3845321
Haematologica. 2006 Feb;91(2):176-83
16461301
J Immunol. 2010 Jan 1;184(1):359-68
19955519
Haematologica. 2010 Jan;95(1):135-43
19773256
Blood. 2009 Dec 17;114(26):5247-8
20018922
Clin Ter. 2000 May-Jun;151(3):187-93
10958054
Clin Cancer Res. 2006 Jan 1;12(1):242-9
16397048
Cancer Res. 2007 Nov 1;67(21):10556-63
17975000
Transplantation. 2000 Sep 27;70(6):963-8
11014650
Proc Natl Acad Sci U S A. 1987 Apr;84(7):2007-11
2436222
Blood. 2010 Jan 21;115(3):592-600
19965652
J Immunol. 2000 Oct 1;165(7):3999-4006
11034410
Oncogene. 2007 May 28;26(25):3629-36
17530016
Mol Immunol. 2007 Sep;44(16):3823-37
17768100
Cell Mol Immunol. 2011 Mar;8(2):157-63
21258360
Nat Med. 2008 Jan;14(1):98-103
18157141
Leuk Res. 2006 May;30(5):625-31
16289746
Blood. 2001 Sep 1;98(5):1352-7
11520782
Mol Immunol. 2003 Sep;40(2-4):109-23
12914817
J Immunol. 2007 May 15;178(10):6616-23
17475893
Am J Hematol. 2009 Feb;84(2):65-70
19051264
Scand J Immunol. 2000 Jun;51(6):634-41
10849376
Oncologist. 2008 Sep;13(9):954-66
18779537
Int J Cancer. 2011 May 1;128(9):2192-201
20635386
J Cell Physiol. 2000 Dec;185(3):317-23
11056001
J Immunol. 2003 Aug 1;171(3):1581-7
12874252
Blood. 2004 Apr 1;103(7):2738-43
14551143
Ann N Y Acad Sci. 2009 Sep;1173:865-73
19758239
Blood. 2001 Dec 1;98(12):3383-9
11719378
J Immunol. 2004 Mar 1;172(5):3280-8
14978136
Eur J Immunol. 2005 Jul;35(7):2175-83
15971270